ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

DXCM DexCom Inc

125.61
-0.27 (-0.21%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
DexCom Inc NASDAQ:DXCM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.27 -0.21% 125.61 124.51 126.60 127.88 124.61 127.03 2,311,411 01:00:00

Dexcom Schedules Fourth Quarter & Full Year 2019 Earnings Release & Conference Call for February 13, 2020 at 4:30 p.m. Easter...

21/01/2020 2:00pm

Business Wire


DexCom (NASDAQ:DXCM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more DexCom Charts.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2019 financial results after market close on Thursday, February 13, 2020. Management will hold a conference call to review the company's fourth quarter and full year 2019 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor relations website at investors.dexcom.com and will be archived there for future reference.

To listen to the conference call, please dial (800) 447-0521 (US/Canada) or (847) 413-3238 (International) and use the confirmation number "49260062" approximately five minutes prior to the start time.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes.

DexCom, Inc.:

Investors Steven R. Pacelli Executive Vice President, Strategy and Corporate Development (858) 200-0200 www.dexcom.com

Media James McIntosh (619) 884-2118

1 Year DexCom Chart

1 Year DexCom Chart

1 Month DexCom Chart

1 Month DexCom Chart

Your Recent History

Delayed Upgrade Clock